|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US7008624B1
(en)
*
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
ATE299938T1
(de)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
DE10045592A1
(de)
*
|
2000-09-15 |
2002-03-28 |
Klaus Pfizenmaier |
Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
|
|
US6942853B2
(en)
|
2001-01-09 |
2005-09-13 |
Queen Mary And Westfield College |
Latent fusion protein
|
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
RS51829B
(sr)
*
|
2001-08-23 |
2012-02-29 |
Genmab A/S. |
Ljudska antitela specifična za interleukin 15 (il-15)
|
|
ES2629395T3
(es)
|
2001-10-04 |
2017-08-09 |
Genetics Institute, Llc |
Métodos y composiciones para modular la actividad de la interleucina-21
|
|
NZ567242A
(en)
|
2001-10-04 |
2009-11-27 |
Genetics Inst Llc |
Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
CN1703423A
(zh)
|
2002-10-14 |
2005-11-30 |
豪夫迈－罗氏公司 |
Il－15拮抗剂
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
WO2005063279A1
(en)
|
2003-12-29 |
2005-07-14 |
Universitätsklinikum Münster |
Means for stimulation and activation of hair growth by il-15
|
|
EP1702069A2
(en)
|
2004-01-05 |
2006-09-20 |
EMD Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
ES2367027T3
(es)
|
2004-02-27 |
2011-10-27 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
|
|
US20060234205A1
(en)
|
2004-03-05 |
2006-10-19 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
AU2007271398B2
(en)
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
|
US8211420B2
(en)
|
2006-12-21 |
2012-07-03 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the IL-21 receptor
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-ｉｌ-12/ｉｌ-23 항체
|
|
NO2344540T3
(enExample)
|
2008-10-02 |
2018-04-28 |
|
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
AU2010215761B2
(en)
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
EP2560994B1
(en)
|
2010-04-08 |
2016-10-12 |
JN Biosciences LLC |
Antibodies to cd122
|
|
WO2012061536A2
(en)
|
2010-11-02 |
2012-05-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EP2665486B1
(en)
|
2011-01-18 |
2019-12-25 |
Bioniz, LLC |
Compositions for modulating gamma-c-cytokine activity
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
PE20141017A1
(es)
|
2011-03-02 |
2014-08-25 |
Roche Glycart Ag |
Anticuerpos del cea
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
PE20150645A1
(es)
|
2012-08-08 |
2015-05-11 |
Roche Glycart Ag |
Proteinas de fusion de interleuquina 10 y usos de las mismas
|
|
US20150359853A1
(en)
*
|
2012-10-24 |
2015-12-17 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
KR20150131208A
(ko)
|
2013-03-13 |
2015-11-24 |
이미지냅 인코포레이티드 |
Cd８에의 항원 결합 구조체들
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
RU2689717C2
(ru)
|
2014-01-08 |
2019-05-28 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Гетеродимерный белок il-15 и его применения
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
AU2015244025B2
(en)
|
2014-04-08 |
2019-03-21 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for IL-21 and uses thereof
|
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
|
PT3172227T
(pt)
|
2014-07-21 |
2019-12-06 |
Delinia Inc |
Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
US20180263925A1
(en)
|
2014-12-03 |
2018-09-20 |
Rxi Pharmaceuticals Corporation |
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
TWI582109B
(zh)
|
2015-01-09 |
2017-05-11 |
美國禮來大藥廠 |
Ｇｉｐ及ｇｌｐ－１共促效劑化合物
|
|
ES2789351T3
(es)
|
2015-01-13 |
2020-10-26 |
Hope City |
Máscaras de enlace peptídico de proteínas de unión a CTLA4
|
|
US20160362469A1
(en)
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
WO2017046200A1
(en)
|
2015-09-16 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
JP7178906B2
(ja)
|
2016-05-19 |
2022-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
MY203000A
(en)
*
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
JP7626577B2
(ja)
|
2016-11-28 |
2025-02-07 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
DK3558369T3
(da)
|
2016-12-21 |
2025-05-19 |
Cephalon Llc |
Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
SG11201909160WA
(en)
*
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
JP2020528878A
(ja)
|
2017-06-20 |
2020-10-01 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
がん治療用インターフェロンプロドラッグ
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
CN110396133B
(zh)
|
2018-04-25 |
2021-07-23 |
免疫靶向有限公司 |
一种以白介素12为活性成分的融合蛋白型药物前体
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
CA3137971A1
(en)
|
2019-05-03 |
2020-11-12 |
Bioniz, Llc |
Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
|
|
EP3980051A4
(en)
|
2019-06-05 |
2023-09-13 |
Asher Biotherapeutics, Inc. |
FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
US20220289822A1
(en)
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
AU2020353235A1
(en)
|
2019-09-28 |
2022-03-31 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
US20240076355A1
(en)
|
2021-01-14 |
2024-03-07 |
AskGene Pharma, Inc. |
Interferon Prodrugs and Methods of Making and Using the Same
|
|
CA3204051A1
(en)
|
2021-01-20 |
2022-07-28 |
Brian Lian |
Compositions and methods for the treatment of metabolic and liver disorders
|
|
CN117500824A
(zh)
|
2021-02-01 |
2024-02-02 |
奥美药业有限公司 |
包含IL-10或TGF-β激动剂多肽的嵌合分子
|
|
WO2022178103A1
(en)
|
2021-02-17 |
2022-08-25 |
AskGene Pharma, Inc. |
Il-2 receptor beta subunit mutants
|
|
JP7642830B2
(ja)
|
2021-09-15 |
2025-03-10 |
バイキング・セラピューティクス・インコーポレイテッド |
代謝及び肝臓障害の処置のための組成物及び方法
|